KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Asset Writedowns and Impairment (2018 - 2025)

Historic Asset Writedowns and Impairment for Edwards Lifesciences (EW) over the last 3 years, with Q3 2025 value amounting to $40.0 million.

  • Edwards Lifesciences' Asset Writedowns and Impairment changed N/A to $40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.1 million, marking a year-over-year change of. This contributed to the annual value of $55.1 million for FY2022, which is 127750.0% up from last year.
  • As of Q3 2025, Edwards Lifesciences' Asset Writedowns and Impairment stood at $40.0 million.
  • Over the past 5 years, Edwards Lifesciences' Asset Writedowns and Impairment peaked at $47.1 million during Q2 2025, and registered a low of $40.0 million during Q3 2025.